Released Jun 14, 2018, after the close
10-Q filed Jun 14, 2018, 45 days after period end · 0001654954-18-006670
Q2 2018 · 10-Q
Revenue$3.77M$3.77M −4.0% vs Q2 2017+1.0% vs Q1 2018
Net Income-$128.35K-$128.35K N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.01-$0.01 N/M vs Q2 2017N/M vs Q1 2018
Gross Profit$1,037,012−0.4%
Operating Income-$8,683N/M
Operating Cash Flow$159,577N/M
Free Cash Flowderived$152,928N/M
Margins · derived
Gross margin27.5%+1.0 pt vs Q2 2017
Operating margin-0.2%+8.0 pt vs Q2 2017
Net margin-3.4%+4.8 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $3.77M | $3.92M | — | — |
| Net Income | -$128.35K | -$322.76K | $37.20K | $359.01K |
| EPS Diluted | -$0.01 | -$0.01 | $0.00 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR